Wet Age-Related Macular Degeneration Market to Flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

Impending patent cliff for the current standard of care to be offset by increasing prevalence and the expected launches of novel therapies during the forecast period (2017–2030)

LAS VEGAS, March 17, 2021 /PRNewswire/ -- DelveInsight's "Wet Age-Related Macular Degeneration (Wet AMD) Market" report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

Some of the vital points of the Wet Age-Related Macular Degeneration Market Research Report 

• The introduction of Anti-vascular endothelial growth factor (VEGF) as a standard Wet AMD treatment has led to a significant improvement in patients' prognosis, allowing recovery and maintenance of visual function in the vast majority of cases. 
• Anti-VEGF medications have been revolutionary for treating neovascular, or exudative, age-related macular degeneration, but unmet needs continue. Firstly, intravitreal injections require frequent and indefinite evaluations, with an exceptionally high burden during the first two treatment years. Secondly, current treatments have a short duration of effect. Lastly, despite robust response and visual gains in many patients, up to 30% may continue to lose vision from baseline due to inadequate choroidal neovascularization response, the progression of atrophy or subretinal fibrosis, and scar formation.
• Some of the dominant players such as Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea Limited, Alkahest, Graybug Vision, PanOptica, Clearside Biomedical, Hemera Biosciences, Ribomic USA Inc., and others are set to influence the global Wet AMD market.
• Wet Age-Related Macular Degeneration Market is positively impacted by an increased prevalence and the expected launch of novel therapies, such as RGX-314, Conbercept, Faricimab, Beovu, Axitinib, HMR59, RBM-007, KSI-301, OPT-302, AKST4290, Sunitinib Malate, RGX-314, PAN-90806, and others during the forecast period (2017–2030). 

For further information on Market Impact by Therapies, visit: Wet AMD Treatment Market Trends

Age-related Macular Degeneration (AMD) is a leading cause of severe, irreversible blindness worldwide, profoundly affecting individuals' quality of life. Wet AMD is a type of AMD characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid that may swell and damage the macula. Wet AMD is also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss. 

According to DelveInsight's analysts, the total diagnosed Wet AMD prevalent population was estimated to be 4,426,968 cases in the 7MM in 2020. Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males. 

The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total prevalent cases
• Gender-specific cases 
• Age-specific cases

Get a sample copy of this report: Wet Age-Related Macular Degeneration Market Landscape

Wet Age-Related Macular Degeneration Treatment Market 

Wet AMD has no cure even though an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients' quality of life. According to the most recent AMD guidelines, the intravitreal administration of antivascular endothelial growth factor agents (anti-VEGF) constitutes the standard of care for Wet AMD patients due to the promising results provided by these therapies during clinical development. 

Angiogenesis inhibitors, the protein that promotes blood vessel growth, work by blocking VEGF activity. The most common and effective clinical treatment for Wet AMD is anti-VEGF therapy, a periodic intravitreal injection of a chemical called an anti-VEGF. Several VEGF therapies have been approved in the market for 7MM. These include Lucentis, Eylea, Macugen, and Boevu. Avastin is also used as an "off-label" drug.

However, the success of anti-VEGF therapy is closely linked to strict intravitreal treatment patterns that seem not to be appropriately addressed in routine clinical practice, conducting more preliminary outcome results for Wet AMD patients than expected according to clinical trials.

Photodynamic therapy (PDT) is most effective in a subtype of Wet AMD known as predominantly classic subfoveal AMD, in which blood vessel growth and leakage in the fovea are well defined. PDT is rarely utilized now since there are drugs (EYLEA, Lucentis, Macugen, and Avastin), which prohibit the vessel-promoting VEGF protein. During the PDT procedure, a drug known as Visudyne is injected into the arm. The drug courses through the body and is absorbed by the fragile, draining blood vessels in the eye.

Laser photocoagulation surgery was the first treatment used for Wet AMD. However, it is only an option for a few patients. During the outpatient procedure, the eye is numbed, and a high-energy laser heats, seals, and damages abnormal leaky blood vessels. This can potentially stop further vision loss; however, it leads to a permanent blind spot because of scarring. Some patients experience mild pain during and/or shortly after the procedure.

Researchers have been suggesting antioxidant vitamins, and other nutrients may reduce AMD progression among people with a high risk of vision loss from macular degeneration. Two large clinical trials sponsored by the National Eye Institute (NEI) called the Age-Related Eye Disease Studies (AREDS and AREDS2) evaluated the effect of nutritional supplements on macular progression degeneration among people with various stages of AMD.

Wet AMD Emerging Therapies Along with Key Players

• Faricimab: Roche
• Conbercept: Chengdu Kanghong Biotech
• KSI-301: Kodiak Sciences Inc.
• OPT-302: Opthea Limited
• AKST4290: Alkahest Inc.
• Sunitinib Malate: Graybug Vision
• RGX-314: REGENXBIO
• PAN-90806: PanOptica, Inc.
• Axitinib: Clearside Biomedical
• HMR59: Hemera Biosciences
• RBM-007: Ribomic USA Inc.

And several others.

Concluding thoughts on Wet Age-Related Macular Degeneration Market Growth 

Wet Age-Related Macular Degeneration Market Drivers 

• Drugs in Pipeline - Many products are in the pipeline like Faricimab, KSI-301, OPT-302, which will help expand the market.
• Diagnosis- Several diagnostic tests have been developed, including fluorescein angiography, indocyanine green angiography, and optical coherence tomography, to help in timely diagnosis. 
• Increased Prevalence - A huge patient pool allows any entrant access to a big market to realize substantial gains.
• Genetic Therapy - Several genetic therapies are being developed, which can yield substantial gains for new entrants. 
• Extensive R&D and Personalized treatment 

Wet Age-Related Macular Degeneration Market Barriers 

• Cost of Therapy - The high cost of therapy with gene therapy presents a considerable hurdle to access treatment. 
• Launch of Biosimilars - There is a lack of biomarkers to predict disease incidence, identify at-risk individuals, elucidate causative pathophysiological etiologies, guide screening, monitoring, and treatment parameters to predict disease outcomes. 
• Future competition among similar drugs - Anti VEGF drugs will compete with each other, which could prove to be a barrier for new entrants. 
• Unmet needs associated with VEGF treatment - There are several unmet needs related to VEGF treatment, including loss of vision in almost 30% of patients getting treatment, and intravitreal injections require frequent and indefinite evaluations.

Scope of the Wet Age-Related Macular Degeneration Market Insight Report 

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Wet Age-Related Macular Degeneration Markets Segmentation: By Geographies and By Wet Age-Related Macular Degeneration Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Wet Age-Related Macular Degeneration: Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea Limited, Alkahest, Graybug Vision, PanOptica, Clearside Biomedical, Hemera Biosciences, Ribomic USA Inc, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies. 
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Wet Age-Related Macular Degeneration Treatment Market Size

Table of Contents 

Browse full report with detailed TOC with charts, figures, tables @ Wet Age-Related Macular Degeneration Treatment Market Share Report 

View Related Reports       

• Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Forecast

DelveInsight's Wet Age-Related Macular Degeneration (Wet AMD) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Wet Age-Related Macular Degeneration (Wet AMD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Wet Age-Related Macular Degeneration (Wet AMD) Pipeline

Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Wet Age-Related Macular Degeneration (Wet AMD) market.

• Age-Related Macular Degeneration Market

DelveInsight's Age-Related Macular Degeneration - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

• Dry Age Macular Degeneration Market 

DelveInsight's Dry Age Macular Degeneration - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. 

• Juvenile Macular Degeneration (JMD) Market 

DelveInsight's Juvenile Macular Degeneration (JMD) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Macular Edema (ME) Market

DelveInsight's Macular Edema (ME) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Macular Telangiectasia Market 

DelveInsight's Macular Telangiectasia- Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Us:

Shruti Thakur
info@delveinsight.com 
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg